Free Trial
NASDAQ:SXTC

China SXT Pharmaceuticals (SXTC) Stock Price, News & Analysis

China SXT Pharmaceuticals logo
$0.32 -0.02 (-5.91%)
(As of 12/20/2024 05:31 PM ET)

About China SXT Pharmaceuticals Stock (NASDAQ:SXTC)

Key Stats

Today's Range
$0.30
$0.36
50-Day Range
$0.32
$0.68
52-Week Range
$0.30
$6.39
Volume
648,493 shs
Average Volume
805,195 shs
Market Capitalization
$1.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

China SXT Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
3rd Percentile Overall Score

SXTC MarketRank™: 

China SXT Pharmaceuticals scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for China SXT Pharmaceuticals.

  • Price to Book Value per Share Ratio

    China SXT Pharmaceuticals has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.10% of the float of China SXT Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    China SXT Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in China SXT Pharmaceuticals has recently increased by 7.61%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    China SXT Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    China SXT Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.10% of the float of China SXT Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    China SXT Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in China SXT Pharmaceuticals has recently increased by 7.61%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    1 people have searched for SXTC on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, China SXT Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.95% of the stock of China SXT Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 5.02% of the stock of China SXT Pharmaceuticals is held by institutions.

  • Read more about China SXT Pharmaceuticals' insider trading history.
Receive SXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for China SXT Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SXTC Stock News Headlines

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals, Inc. (SXTC)
Dow Down 100 Points; US Manufacturing PMI Falls In December
See More Headlines

SXTC Stock Analysis - Frequently Asked Questions

China SXT Pharmaceuticals' stock was trading at $3.97 at the beginning of the year. Since then, SXTC shares have decreased by 91.9% and is now trading at $0.32.
View the best growth stocks for 2024 here
.

China SXT Pharmaceuticals's stock reverse split on the morning of Thursday, October 5th 2023. The 1-25 reverse split was announced on Wednesday, October 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of SXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that China SXT Pharmaceuticals investors own include MARA (MARA), NIO (NIO), Meta Platforms (META), Alibaba Group (BABA), HEXO (HEXO), JD.com (JD) and Blink Charging (BLNK).

Company Calendar

Today
12/21/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SXTC
Fax
N/A
Employees
90
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.93 million
Book Value
$30.46 per share

Miscellaneous

Free Float
3,902,000
Market Cap
$1.30 million
Optionable
Not Optionable
Beta
1.11
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:SXTC) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners